Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

• Published in: EMBO molecular medicine Vol. 11; no. 12; pp. e11170 - n/a
• Main Authors: Palmqvist, Sebastian, Insel, Philip S, Stomrud, Erik, Janelidze, Shorena, Zetterberg, Henrik, Brix, Britta, Eichenlaub, Udo, Dage, Jeffrey L, Chai, Xiyun, Blennow, Kaj, Mattsson, Niklas, Hansson, Oskar
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-12-2019; EMBO Press; John Wiley and Sons Inc; Springer Nature
• Subjects: Aged; Alzheimer disease; Alzheimer Disease - blood; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid; Amyloid beta-Peptides - metabolism; amyloid positron emission tomography; beta; Biomarkers; Biomarkers - blood; Biomarkers - cerebrospinal fluid; Brain research; cerebrospinal; Cerebrospinal fluid; cerebrospinal fluid biomarkers; Clinical Medicine; Clinical trials; Cognitive ability; cognitive decline; Dementia; EMBO02; EMBO27; Female; fluid biomarkers; Humans; Hypotheses; Inflammation; Klinisk medicin; Male; markers; Medical and Health Sciences; Medicin och hälsovetenskap; Neurodegeneration; Neurodegenerative diseases; neurofilament light; Neurogranin; Neurologi; Neurology; Neurosciences; Neurovetenskaper; Pathogenesis; plasma biomarkers; Positron emission tomography; protein; Research & Experimental Medicine; tau; Tau protein; tau Proteins - blood; tau Proteins - cerebrospinal fluid; trial; Europe; cerebrospinal fluid biomarkers; amyloid positron emission tomography; plasma biomarkers; Alzheimer disease
• ISSN: 1757-4676; 1757-4684; 1757-4684
• DOI: 10.15252/emmm.201911170

Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease mechanisms and alterations of biomarkers during the development of AD. Using cross‐sectional data from 377 participants in the BioFINDER study, we examined seven cerebrospinal fluid (CSF) and six plasma biomarkers in relation to β‐amyloid (Aβ) PET uptake to understand their evolution during AD. In CSF, Aβ42 changed first, closely followed by Aβ42/Aβ40, phosphorylated‐tau (P‐tau), and total‐tau (T‐tau). CSF neurogranin, YKL‐40, and neurofilament light increased after the point of Aβ PET positivity. The findings were replicated using Aβ42, Aβ40, P‐tau, and T‐tau assays from five different manufacturers. Changes were seen approximately simultaneously for CSF and plasma biomarkers. Overall, plasma biomarkers had smaller dynamic ranges, except for CSF and plasma P‐tau which were similar. In conclusion, using state‐of‐the‐art biomarkers, we identified the first changes in Aβ, closely followed by soluble tau. Only after Aβ PET became abnormal, biomarkers of neuroinflammation, synaptic dysfunction, and neurodegeneration were altered. These findings lend
in vivo
support of the amyloid cascade hypotheses in humans.
Synopsis
Analysis of the evolution of 13 key cerebrospinal and plasma biomarkers in relation to increasing Aβ accumulation during Alzheimer's disease confirms the amyloid hypothesis, and highlight the presence of other disease mechanisms already prior to the threshold for amyloid positivity.
Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease mechanisms and alterations of biomarkers during the development of AD.
The study examines seven cerebrospinal fluid (CSF) and six plasma biomarkers in relation to β‐amyloid (Aβ) PET uptake to understand their evolution during AD.
The first changes were seen in Aβ biomarkers, closely followed by soluble tau, and then approximately simultaneously in markers of neuroinflammation, synaptic dysfunction and neurodegeneration.
The results were replicated using five different CSF assays for Aβ42, Aβ40, P‐tau and T‐tau.
Graphical Abstract
Analysis of the evolution of 13 key cerebrospinal and plasma biomarkers in relation to increasing Aβ accumulation during Alzheimer's disease confirms the amyloid hypothesis, and highlight the presence of other disease mechanisms already prior to the threshold for amyloid positivity.